CXCR1/2 antagonism with CXCL8/Interleukin-8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis

Oncotarget

Volumn 6, Issue 25, 2015, Pages 21315-21327

  Khan, Muhammad Noman ^a   Wang, Bing ^a   Wei, Jing ^a   Zhang, Yingqiu ^a   Li, Qiang ^b   Luan, Xuelin ^a   Cheng, Jya Wei ^c   Gordon, John R ^d   Li, Fang ^a   Liu, Han ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b JILIN MEDICAL COLLEGE   (China)

^c NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^d ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

CXCR antagonist; ELR CXC chemokine; G31P; Lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 8; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; G31P PROTEIN; INTERLEUKIN 8; INTERLEUKIN 8 DERIVATIVE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; VASCULOTROPIN; CXCL8(3-72)K11R,G31P, HUMAN; LIGAND; PEPTIDE FRAGMENT;

A549 CELL LINE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER MODEL; CANCER TISSUE; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME PHOSPHORYLATION; FEMALE; H460 CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LUNG CANCER CELL LINE; METASTASIS INHIBITION; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR BLOCKING; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CARCINOMA, NON-SMALL-CELL LUNG; CELL MOTION; CHEMISTRY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; LUNG NEOPLASMS; MALE; METABOLISM; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-8; LIGANDS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; RECEPTORS, INTERLEUKIN-8A; RECEPTORS, INTERLEUKIN-8B;

EID: 84940754396     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and death to 2030. The unexpected burden of thyroid. liver, and pancreas cancer in the United States. Cancer Res. 2014; 74:2913-2921.
2. She J, Yang P, Hong Q, Bai C. Lung cancer in China: Challenges and interventions. Chest. 2013; 143:1117-26.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
4. Wang JM, Deng X, Gong W, Su S. Chemokines and their role in tumor growth and metastasis. J Immunol Methods. 1998; 220:1-17.
5. Vandercappellen J, Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett. 2008; 267:226-44.
6. Raman D, Baugher PJ, Thu YM, Richmond A. Role of chemokines in tumor growth. Cancer Lett. 2007; 256:137-65.
7. Zlotnik A. Chemokines and cancer. Int J Cancer. 2006; 119:2026-2029.
8. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer. 2006; 51:143-158.
9. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wangner SN, Barrera JL. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001; 410:50-6.
10. Sun YX, Wang J, Shelburne CE, Lopatin DE, Chinnaiyan AM, Rubin MA, Pienta KJ, Taichman RS. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J. Cell. Biochem. 2003; 89:462-473.
11. Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR. Epithelial cancer cell migration: a role for chemokine receptor? Cancer Res. 2001; 61:4961-5.
12. Li A, Varney ML, Singh RK. Expression of interleukin 8 and its receptors in human colon carcinoma with different metastatic potentials. Clin. Cancer Res. 2001; 7:3298-304.
13. Lee J, Horuk R, Rice GC, Bennett GL, Camerato T, Wood WI. Characterization of two high affinity human interleukin-8 receptors. J Biol. Chem. 1992; 267:16283-7.
14. Singh S, Michelle V, Rakesh KS. Host CXCR2 dependent regulation of melanoma growth, angiogenesis and experimental lung metastasis. Cancer Res. 2009; 69:411-415.
15. Keane MP, Belperio JA, Xue YY, Burdick MD, Strieter RM. Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol. 2004; 172:2853-60.
16. Rot A, von Andrian UH. Chemokines in innate and adaptive host defense basic chemokinese grammar for immune cells. Annual Rev. Immunol. 2004; 22:891-928.
17. Orditura M, DeVita F, Catalano G, Infusino S, Lieto E, Martinelli E, Morgillo F, Castellano P, Pignatelli C, Galizia G. Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis. J Interferon Cytokine Res. 2002; 22:1129-1135.
18. Zhu YM, Webster SJ, Flower D, Woll PJ. Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Br J Cancer. 2004; 91:1970-1976.
19. Yuan A, Yang PC, Yu CJ, Chen WJ, Lin FY, Kuo SH, Luh KT. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patients survival and timing of relapse in non-small-cell lung cancer. Am J Respir Crit Care Med. 2000; 162:1957-1963.
20. Chen JJW, Yao PL, Yuan A, Hong TM, Shun CT, Kuo ML, Lee YC, Yang PC. Upreulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res. 2003; 9:729-737.
21. Zhao X, Town JR, Li F, Zhang X, Cockcroft DW, Gordon JR. ELR-CXC Chemokine receptor antagonism targets inflammatory responses at multiple levels. J Immunol. 2009; 182:3213-3222.
22. Gordon JR, Li F, Zhang X. The combined CXCR1/CXCR2 antagonist CXCL8 (3-74)K11R/G31P blocks neutrophil infiltration, pyrexia and pulmonary vascular pathology in endotoxemic animals. Leukoc Biol. 2005; 78:1265-1272.
23. Zhao X, Town JR, Zhang X, Li F, Li W, Gordon JR. Blockade of neutrophil responses in aspiration pneumonia via ELR-CXC chemokine antagonism does not predispose to airway bacterial outgrowth. Pulm. Pharmacol. Ther. 2009; 23:22-28.
24. Liu X, Peng J, Sun W, Yang S, Deng G, Li F, Cheng JW, Gordon JR. G31P, an antagonist against CXC chemokines receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice. Tohoku J Exp Med. 2012; 228:147-56.
25. Li L, Khan MN, Li Q, Chen X, Wei J, Wang B, Cheng JW, Gordon JR, Li F. G31P, CXCR1/2 inhibitor, with cisplatin inhibits the growth of mice hepatocellular carcinoma and mitigates high-dose cisplatin-induced nephrotoxicity. Oncol Rep. 2015; 33:751-7.
26. Lippitz BE. Cytokine patterns in patients with cancer: a systemic review. Lancet Oncol. 2013; 14:218-28.
27. Huang S, DeGuzman A, Bucana CD, Fidler IJ. Nuclear factor-κB activity correlates with growth, angiogenesis and metastasis of human melanoma cells in nude mice. Clin Cancer Res. 2000; 6:2573-2581.
28. (3-73)K11R is a high affinity agonist of the neutrophil CXCR1 and CXCR2. Biochem Biophys Res Comm. 2011; 286:595-600.
29. Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD, Strieter RM. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest. 1996; 97:2792-2802.
30. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420:860-7.
31. Kruas-Berthier L, Jan M, Guilbaud N, Naze M, Pierre A, Atassi G. Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice. Clin Cancer Res. 2000; 6:297-304.
32. Campbell LM, Maxwell PJ, Waugh DJ. Rationale and Means to Target Pro-Inflammatory Interleukin-8 (CXCL8) Signaling in Cancer. Pharmaceuticals. 2013; 6:929-959.
33. Allavena P, Germano G, Marchesi F, Mantovani A. Chemokines in cancer related inflammation. Exp Cell Res. 2011; 317:664-673.
34. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008; 14:6735-6741.
35. Knall C, Worthen GS, Johnson GL. Interleukin-8 stimulated phosphatidylinositol-3-kinase activity regulates the migration of human neutrophils independent of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase. Proc. Natl. Acad. Sci. 1997; 94:3052-3057.
36. Schraufstatter IU, Chung J, Burger M. IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways. Am J Physiol Lung Cell Mol Physiol. 2001; 280:1094-1103.